WVE-N531

Wave Life Sciences will pursue FDA accelerated approval for WVE-N531, an exon 53 skipping therapy for Duchenne muscular dystrophy, following positive Phase 2 trial results showing increased dystrophin production.

Anova Enterprises initiates Phase I/IIa trial of DB107, a revolutionary gene therapy combining retroviral vectors and oral prodrugs for treating high-grade gliomas with reduced systemic toxicity.

The FDA is set to decide on Biogen and Eisai's Leqembi for monthly intravenous maintenance in early Alzheimer's disease, potentially improving patient convenience.

Wave Life Sciences is set to initiate dosing for WVE-007 in its Phase 1 INLIGHT trial for obesity in Q1 2025, with proof-of-concept data expected later in the year.

Sarepta Therapeutics' Elevidys demonstrates sustained benefits and disease stabilization in ambulatory Duchenne muscular dystrophy (DMD) patients, according to Phase 3 EMBARK trial results.